PURPOSE: To test the therapeutic efficacy of azithromycin (AZM), a macrolide antibiotic for prolonging murine "high-risk" corneal allograft survival. METHODS: Fully major histocompatibility complex-mismatched corneas were transplanted from C57BL/6 donors to BALB/c recipients with suture-induced vascularized high-risk corneal beds. Recipient mice were either not treated or treated with topical AZM, oral AZM, or both. Evaluation of graft vascularization and clarity was performed in a masked fashion. Lymph nodes were excised and analyzed for CD4, FoxP3, and CD44 by flow cytometry, and for T-cell priming by proliferation and cytokine production in mixed lymphocyte cultures. Corneal whole mounts were evaluated by confocal microscopy. RESULTS: The incidence of graft rejection in the control group (81.8%) was significantly reduced by AZM treatment (18.2% topical, 21.7% oral, 33.3% topical + oral), although corneal vascularization was not affected by the treatment. The frequency of corneas that retained complete clarity after transplantation was higher in the AZM-treated groups. Reduced graft rejection in the AZM-treated groups was not associated with a reduced allospecific T-cell response or increased frequency of regulatory T cells. CONCLUSIONS: AZM is effective in prolonging survival of high-risk corneal allografts by an as yet undefined mechanism that does not seem to involve modulation of corneal neovascularization or allospecific T-cell priming.
PURPOSE: To test the therapeutic efficacy of azithromycin (AZM), a macrolide antibiotic for prolonging murine "high-risk" corneal allograft survival. METHODS: Fully major histocompatibility complex-mismatched corneas were transplanted from C57BL/6 donors to BALB/c recipients with suture-induced vascularized high-risk corneal beds. Recipient mice were either not treated or treated with topical AZM, oral AZM, or both. Evaluation of graft vascularization and clarity was performed in a masked fashion. Lymph nodes were excised and analyzed for CD4, FoxP3, and CD44 by flow cytometry, and for T-cell priming by proliferation and cytokine production in mixed lymphocyte cultures. Corneal whole mounts were evaluated by confocal microscopy. RESULTS: The incidence of graft rejection in the control group (81.8%) was significantly reduced by AZM treatment (18.2% topical, 21.7% oral, 33.3% topical + oral), although corneal vascularization was not affected by the treatment. The frequency of corneas that retained complete clarity after transplantation was higher in the AZM-treated groups. Reduced graft rejection in the AZM-treated groups was not associated with a reduced allospecific T-cell response or increased frequency of regulatory T cells. CONCLUSIONS:AZM is effective in prolonging survival of high-risk corneal allografts by an as yet undefined mechanism that does not seem to involve modulation of corneal neovascularization or allospecific T-cell priming.
Authors: H Takizawa; M Desaki; T Ohtoshi; S Kawasaki; T Kohyama; M Sato; M Tanaka; T Kasama; K Kobayashi; J Nakajima; K Ito Journal: Am J Respir Crit Care Med Date: 1997-07 Impact factor: 21.405
Authors: H Takizawa; M Desaki; T Ohtoshi; T Kikutani; H Okazaki; M Sato; N Akiyama; S Shoji; K Hiramatsu; K Ito Journal: Biochem Biophys Res Commun Date: 1995-05-25 Impact factor: 3.575
Authors: R M Strieter; K Kasahara; R M Allen; T J Standiford; M W Rolfe; F S Becker; S W Chensue; S L Kunkel Journal: Am J Pathol Date: 1992-08 Impact factor: 4.307
Authors: Alexander M Rowe; Hongming Yun; Benjamin R Treat; Paul R Kinchington; Robert L Hendricks Journal: J Immunol Date: 2017-01-06 Impact factor: 5.422
Authors: Alja Crnej; Masahiro Omoto; Thomas H Dohlman; Claes H Dohlman; Reza Dana Journal: Invest Ophthalmol Vis Sci Date: 2014-12-16 Impact factor: 4.799
Authors: Katrin Wacker; Sophy Denker; Antonia Hildebrand; Philipp Eberwein; Thomas Reinhard; Johannes Schwartzkopff Journal: PLoS One Date: 2013-12-09 Impact factor: 3.240